12 / 64
Anales Oftalmológicos
Tomo VI Vol. II N˚1-2-3 · 2011 · Santiago - Chile
14. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See
RF, Letko E, et al. Initial evaluation of subcutaneous
daclizumab treatments for noninfectious uveitis: a
multicenter noncomparative interventional case
series.Ophthalmology. 2005;112:764–770.
15. Plskova J, Greiner K, Forrester JV. Interferon-
alpha as an effective treatment for noninfectious
posterior uveitis and panuveitis. Am J Ophthalmol.
2007;144:55–61.
16. Plskova J, Greiner K, Muckersie E, Duncan L,
Forrester JV. Interferon-alpha: a key factor in
autoimmune disease? Invest Ophthalmol Vis Sci.
2006;47:3946–3950.
17. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness
T, Günaydin I, et al. Human recombinant interferon
alfa-2a for the treatment of Behcet’s disease with
sight threatening posterior or panuveitis. Br J
Ophthalmol.2003;87:423–431.
18. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M.
Results of interferon-alfa therapy in patients with
Behcet uveitis. Graefes Arch Clin Exp Ophthalmol.
2006;244:1692–1695.
19. Bodaghi B, Gendron G, Wechsler B, Terrada C,
Cassoux N, Huong du LT, et al. Efficacy of interferon
alpha in the treatment of refractory and sight
threatening uveitis: a retrospective monocentric study
of 45
patients.BrJ Ophthalmol. 2007;91:335–339.
20. Becker MD, Heiligenhaus A, Hudde T, Storch-
Hagenlocher B, Wildemann B, Barisani-Asenbauer
T, et al. Interferon as a treatment for uveitis
associated with multiple sclerosis. Br J Ophthalmol.
2005;89:1254–1257.
21. Dick A, Meyer P, James T, Forrester JV, Hale G,
Waldmann H, et al. Campath-1H therapy in refractory
ocular inflammatory diseases. Br J Ophthalmol.
2000;84:107–109.
22. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross
WL. Successful treatment of refractory anterior scleritis
in primary Sjorgen’s syndrome with rituximab. Ann
Rheum Dis. 2005;64:1087–1088.
BIBLIOGRAFÍA